TY - JOUR
T1 - Overview of BioBank Japan follow-up data in 32 diseases
AU - BioBank Japan Cooperative Hospital Group
AU - Hirata, Makoto
AU - Nagai, Akiko
AU - Kamatani, Yoichiro
AU - Ninomiya, Toshiharu
AU - Tamakoshi, Akiko
AU - Yamagata, Zentaro
AU - Kubo, Michiaki
AU - Muto, Kaori
AU - Kiyohara, Yutaka
AU - Mushiroda, Taisei
AU - Murakami, Yoshinori
AU - Yuji, Koichiro
AU - Furukawa, Yoichi
AU - Zembutsu, Hitoshi
AU - Tanaka, Toshihiro
AU - Ohnishi, Yozo
AU - Nakamura, Yusuke
AU - Matsuda, Koichi
AU - Shiono, Masaki
AU - Misumi, Kazuo
AU - Kaieda, Reiji
AU - Harada, Hiromasa
AU - Minami, Shiro
AU - Watanabe, Atsushi
AU - Emoto, Naoya
AU - Takahashi, Kazuhisa
AU - Takeda, Satoru
AU - Funaki, Toshinari
AU - Asai, Satoshi
AU - Moriyama, Mitsuhiko
AU - Takahashi, Yasuo
AU - Fujioka, Tomoaki
AU - Obara, Wataru
AU - Mori, Seijiro
AU - Ito, Hideki
AU - Nagayama, Satoshi
AU - Miki, Yoshio
AU - Masumoto, Akihide
AU - Yamada, Akira
AU - Nishizawa, Yasuko
AU - Kodama, Ken
AU - Kutsumi, Hiromu
AU - Sugimoto, Yoshihisa
AU - Koretsune, Yukihiro
AU - Kusuoka, Hideo
AU - Yoshimori, Kozo
N1 - Publisher Copyright:
© 2017 The Authors.
PY - 2017
Y1 - 2017
N2 - Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).
AB - Background: We established a patient-oriented biobank, BioBank Japan, with information on approximately 200,000 patients, suffering from any of 47 common diseases. This follow-up survey focused on 32 diseases, potentially associated with poor vital prognosis, and collected patient survival information, including cause of death. We performed a survival analysis for all subjects to get an overview of BioBank Japan follow-up data. Methods: A total of 141,612 participants were included. The survival data were last updated in 2014. KaplaneMeier survival analysis was performed after categorizing subjects according to sex, age group, and disease status. Relative survival rates were estimated using a survival-rate table of the Japanese general population. Results: Of 141,612 subjects (56.48% male) with 1,087,434 person-years and a 97.0% follow-up rate, 35,482 patients died during follow-up. Mean age at enrollment was 64.24 years for male subjects and 63.98 years for female subjects. The 5-year and 10-year relative survival rates for all subjects were 0.944 and 0.911, respectively, with a median follow-up duration of 8.40 years. Patients with pancreatic cancer had the least favorable prognosis (10-year relative survival: 0.184) and patients with dyslipidemia had the most favorable prognosis (1.013). The most common cause of death was malignant neoplasms. A number of subjects died from diseases other than their registered disease(s).
UR - http://www.scopus.com/inward/record.url?scp=85016390491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016390491&partnerID=8YFLogxK
U2 - 10.1016/j.je.2016.12.006
DO - 10.1016/j.je.2016.12.006
M3 - Article
C2 - 28190660
AN - SCOPUS:85016390491
SN - 0917-5040
VL - 27
SP - S22-S28
JO - Journal of epidemiology
JF - Journal of epidemiology
IS - 3
ER -